Antiobesity effects of A-331440, a novel non-imidazole histamine H 3 receptor antagonist

European Journal of Pharmacology

Volumn 487, Issue 1-3, 2004, Pages 183-197

  Hancock, Arthur A ^a   Bennani, Youssef L ^a,b   Bush, Eugene N ^a   Esbenshade, Timothy A ^a   Faghih, Ramin ^a   Fox, Gerard B ^a   Jacobson, Peer ^a   Knourek Segel, Victoria ^a   Krueger, Kathleen M ^a   Nuss, Merrill E ^a   Pan, Jia Bao ^a   Shapiro, Robin ^a   Witte, David G ^a   Yao, Betty B ^a  

^a ABBOTT LABORATORIES   (United States)

^b ATHERSYS INC   (United States)

Author keywords

Antiobesity; Histamine H3 receptor antagonist; Magnetic resonance imaging

Indexed keywords

4' [3 [3 (DIMETHYLAMINO)PYRROLIDIN 1 YL]PROPOXY]BIPHENYL 4 CARBONITRILE; A 331440; ANTIOBESITY AGENT; CIPROXIFAN; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; THIOPERAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SELECTIVITY; EMBRYO; FLUID INTAKE; FOOD INTAKE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; INSULIN TOLERANCE TEST; LIPID DIET; LOW FAT DIET; MOUSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; REDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BEHAVIOR, ANIMAL; BIPHENYL COMPOUNDS; BODY COMPOSITION; BODY WEIGHT; CALCIUM; CLONING, MOLECULAR; DIAGNOSTIC IMAGING; DIET; DIETARY FATS; FENFLURAMINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HISTAMINE ANTAGONISTS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; NITRILES; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, HISTAMINE H3; WEIGHT LOSS;

EID: 12144289304     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.01.015     Document Type: Article

References (48)

1. 3) of histamine receptor. Nature. 30:1983;832-837.
2. Beckman N., Gentsch C., Baumann D., Bruttel K., Vassout A., Schoeffter P., Loetscher E., Bobadilla M., Perentes E., Rudin M. Non-invasive, quantitative assessment of the anatomical phenotype of corticotropin-releasing factor-overexpressing mice by MRI. NMR Biomed. 14:2001;210-216.
3. Bjenning C., Johannesson U., Juul A.-G., Lange J.Z., Rimvall K. Peripherally administered ciproxifan elevates hypothalamic histamine levels and potently reduces food intake in the Sprague Dawley rat. Abstracts, International Sendai Histamine Symposium. 2000;144 Japanese Histamine Research Society, Sendai, Japan. # P-39.
4. 3 antagonist potently reduces snacking behavior in the obese Zucker rat. Abstracts, International Sendai Histamine Symposium. 2000;145 Japanese Histamine Research Society, Sendai, Japan. # P-40.
5. Bonetta L. Scientists battle obesity overload. Nat. Med. 7:2001;387.
6. Changani K.K., Nicholson A., White A., Latcham J.K., Reid D.G., Clapham J.C. A longitudinal magnetic resonance imaging (MRI) study of differences in abdominal fat distribution between normal mice, and lean overexpressors of mitochondrial uncoupling protein-3 (UCP-3). Diabetes Obes. Metab. 5:2003;99-105.
7. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
8. Clapham J.C., Arch J.R.S., Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol. Ther. 89:2001;81-121.
9. Coward P., Chan S., Wada H., Humphries G., Conklin B. Chimeric G-proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal. Biochem. 270:1999;242-248.
10. DeSouza C.J., Eckhardt M., Gagen K., Mei D., Wei C., Didier L., Burkey B.F. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabet. 50:2001;1863-1871.
11. Esbenshade T.E., Hancock A.A. Characterization of histaminergic receptors. Enna S., Williams M., Ferkany J., Kenakin T., Porsolt R., Sullivan J. Current Protocols in Pharmacology. 2000;1.19.1-1.19.22 Wiley, New York, NY.
12. Esbenshade T., Krueger K., Denny L.I., Miller T., Kang C.H., Witte D., Yao B., Black L., Bennani Y., Decker M., Pan J., Fox G., Hancock A. Complex pharmacological effects of GT-2331. Abstracts. 2001;Society for Neuroscience, Washington, DC, USA. # 378.11.
13. 3 receptor antagonists, A-304121 and A-317920: 1. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 305:2003;887-896.
14. 3-receptor ligands: II. Binding preference for D-amino-acid motifs. Bioorg. Med. Chem. Lett. 12:2002;2034-2037.
15. Faghih R., Dwight W., Vasudevan A., Dinges J., Conner S.E., Esbenshade T., Bennani Y., Hancock A.A. Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett. 12:2002;3077-3079.
16. Fox G.B., Pan J.B., Kang C.H., Yao B.B., Miller T.R., Denny L.I., Parihar A.S., Komater V., Bennani Y.L., Esbenshade T.A., Hancock A.A., Decker M.W. In vivo and ex vivo effects of ciproxifan and methylphenidate following repeated administration. Abstracts. 2001;Society for Neuroscience, Washington, DC, USA. #539.1.
17. 3 receptor ligands in a new mouse dipsogenia model. Pharmacol. Biochem. Behav. 72:2002;741-750.
18. Gumbiner B., Battiwalla M. Obesity and type 2 diabetes mellitus: a treatment challenge. Endocrinologist. 12:2002;23-28.
19. Hauner H. Current pharmacological approaches to the treatment of obesity. Int. J. Obes. 25(Suppl. 1):2001;S102-S106.
20. Hough L.B. Genomics meets histamine receptors: new subtypes, new receptors. Mol. Pharmacol. 59:2001;415-419.
21. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia (Berl.). 13:1968;222-257.
22. 3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol. Psychiatry. 45:1999;475-481.
23. 3 receptor expression during rat development and in adult rat peripheral tissues. Abstracts. 2001;Society for Neuroscience, Washington, DC, USA. # 378.9.
24. 3 receptor antagonist, A-331440. Pharmacologist. 44(Suppl. 1):2002;A196.
25. Kuczmarski R.J., Flegal K.M., Campbell S.M., Johnson C.L. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. J. Am. Med. Assoc. 272:1994;205-211.
26. Laurent W.M., Bonny J.M., Renou J.P. Imaging of water and fat fractions in high-field MRI with multiple slice chemical shift-selective inversion recovery. J. Magn. Reson. Imaging. 12:2000;488-496.
27. Leonhardt M., Hrupka B., Langhans W. New approaches in the pharmacological treatment of obesity. Eur. J. Nutr. 38:1999;1-13.
28. 3 receptor agonists and antagonists. TIPS. 19:1998;177-183.
29. 3 receptors: role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. 131:2000;1247-1250.
30. 4) expressed in bone marrow. Mol. Pharmacol. 59:2001;420-426.
31. 3 receptor. Mol. Pharmacol. 55:1999;1101-1107.
32. 3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. 293:2000;771-778.
33. Lin J.H., Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35:1998;361-390.
34. Martin L.F., Robinson A., Moore B.J. Socioeconomic issues affecting the treatment of obesity in the new millennium. Pharmacoeconomics. 18:2000;335-353.
35. Morimoto T., Yamamoto Y., Mobarekeh J.I., Yanai K., Watanabe T., Watanabe T., Yamatodani I. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav. 67:1999;679-683.
36. Morimoto T., Yamamoto Y., Yamatodani A. Brain histamine and feeding behavior. Behav. Brain Res. 124:2001;145-150.
37. 3 receptors regulates histamine neurons in brain. Nature. 408:2000;860-864.
38. Oda T., Morikawa N., Saito Y., Masuho Y., Matsumoto S. Molecular cloning and characterization of novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275:2000;36781-36876.
39. 3 receptors? Eur. J. Pharmacol. 184:1990;135-142.
40. Orthen-Gambill N., Salomon M. FMS-induced decrease in central histamine levels produces increased feeding and body weight in rats. Physiol. Behav. 51:1992;891-893.
41. Osculati F., Leclercq F., Sbarbati A., Zancanaro C., Cinti S., Antonakis K. Morphological identification of brown adipose tissue by magnetic resonance imaging in the rat. Eur. J. Radiol. 9:1989;112-114.
42. Ross R., Leger L., Guardo R., De Guise J., Pike B. Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats. J. Appl. Physiol. 70:1991;2164-2172.
43. Sakata T., Yoshimatsyu H., Kurokawa M. Hypothalamic neuronal histamine-implications of its homeostatic control of energy metabolism. Nutrition. 13:1997;403-411.
44. 3-receptor antagonist thioperamide in rats. Farmaco. 52:1997;457-462.
45. 3 receptor ligands. J. Pharmacol. Exp. Ther. 289:1999;1160-1168.
46. 3 antagonists. J. Pharmacol. Exp. Ther. 299:2001;908-914.
47. Yao B.B., Hutchins C.W., Carr T.L., Cassar S., Miller T.R., Kang C.H., Black L.A., Faghih R., Bennani Y.L., Esbenshade T.A., Hancock A.A. Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity. Neuropharmacology. 44:2003;773-786.
48. 3 receptor antagonist, GT-2394, on food intake and weight gain in Sprague-Dawley rats. Abstracts. 2000;Society for Neuroscience, Washington, DC, USA. # 102.10.